Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash

Jesper Grau Eriksen, Inger Kaalund, Ole Clemmensen, Jens Overgaard, Per Pfeiffer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

PURPOSE: Cetuximab inhibits the epidermal growth factor receptor (EGFR), and papulopustular eruptions is a frequent side effect. Vitamin K3 (menadione) has preclinically shown to be a potential activator of the EGFR by phosphorylating the receptor (pEGFR). The present randomised study investigated the effect of a vitamin K3 cream on cetuximab-induced rash.

MATERIALS AND METHODS: Thirty patients were included in this double-blinded placebo-controlled trial. Patients receiving cetuximab 500 mg/m(2) every second week plus chemotherapy for metastatic cancer were included. In each patient, vitamin K3 cream and placebo were applied twice daily on two separate areas of the skin of minimum 10 × 10 cm for up to 2 months. Papulopustular eruptions were evaluated clinically and monitored by clinical photos. Skin biopsies, from ten patients taken before and after 1 month of treatment from each treatment area, were stained for EGFR and pEGFR.

RESULTS: Application of vitamin K3 cream twice daily during treatment with cetuximab did not reduce the number of papulopustular eruptions, and this was independent of the use of systemic tetracycline. No significant changes in the staining of EGFR or pEGFR were observed in the skin of the vitamin K3-treated area compared to the placebo area.

CONCLUSION: The present data do not support any clinical or immunohistochemical benefit of using vitamin K3 cream for cetuximab-induced rash.

OriginalsprogEngelsk
TidsskriftSupportive Care in Cancer
Vol/bind25
Udgave nummer7
Sider (fra-til)2179–2185
ISSN0941-4355
DOI
StatusUdgivet - 2017

Fingeraftryk

Vitamin K 3
Exanthema
Placebos
Epidermal Growth Factor Receptor
Skin
Cetuximab

Citer dette

Eriksen, Jesper Grau ; Kaalund, Inger ; Clemmensen, Ole ; Overgaard, Jens ; Pfeiffer, Per. / Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash. I: Supportive Care in Cancer. 2017 ; Bind 25, Nr. 7. s. 2179–2185.
@article{f1718211e0a440e58723c851ceed89c5,
title = "Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash",
abstract = "PURPOSE: Cetuximab inhibits the epidermal growth factor receptor (EGFR), and papulopustular eruptions is a frequent side effect. Vitamin K3 (menadione) has preclinically shown to be a potential activator of the EGFR by phosphorylating the receptor (pEGFR). The present randomised study investigated the effect of a vitamin K3 cream on cetuximab-induced rash.MATERIALS AND METHODS: Thirty patients were included in this double-blinded placebo-controlled trial. Patients receiving cetuximab 500 mg/m(2) every second week plus chemotherapy for metastatic cancer were included. In each patient, vitamin K3 cream and placebo were applied twice daily on two separate areas of the skin of minimum 10 × 10 cm for up to 2 months. Papulopustular eruptions were evaluated clinically and monitored by clinical photos. Skin biopsies, from ten patients taken before and after 1 month of treatment from each treatment area, were stained for EGFR and pEGFR.RESULTS: Application of vitamin K3 cream twice daily during treatment with cetuximab did not reduce the number of papulopustular eruptions, and this was independent of the use of systemic tetracycline. No significant changes in the staining of EGFR or pEGFR were observed in the skin of the vitamin K3-treated area compared to the placebo area.CONCLUSION: The present data do not support any clinical or immunohistochemical benefit of using vitamin K3 cream for cetuximab-induced rash.",
keywords = "Journal Article",
author = "Eriksen, {Jesper Grau} and Inger Kaalund and Ole Clemmensen and Jens Overgaard and Per Pfeiffer",
year = "2017",
doi = "10.1007/s00520-017-3623-x",
language = "English",
volume = "25",
pages = "2179–2185",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Heinemann",
number = "7",

}

Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash. / Eriksen, Jesper Grau; Kaalund, Inger ; Clemmensen, Ole; Overgaard, Jens; Pfeiffer, Per.

I: Supportive Care in Cancer, Bind 25, Nr. 7, 2017, s. 2179–2185.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash

AU - Eriksen, Jesper Grau

AU - Kaalund, Inger

AU - Clemmensen, Ole

AU - Overgaard, Jens

AU - Pfeiffer, Per

PY - 2017

Y1 - 2017

N2 - PURPOSE: Cetuximab inhibits the epidermal growth factor receptor (EGFR), and papulopustular eruptions is a frequent side effect. Vitamin K3 (menadione) has preclinically shown to be a potential activator of the EGFR by phosphorylating the receptor (pEGFR). The present randomised study investigated the effect of a vitamin K3 cream on cetuximab-induced rash.MATERIALS AND METHODS: Thirty patients were included in this double-blinded placebo-controlled trial. Patients receiving cetuximab 500 mg/m(2) every second week plus chemotherapy for metastatic cancer were included. In each patient, vitamin K3 cream and placebo were applied twice daily on two separate areas of the skin of minimum 10 × 10 cm for up to 2 months. Papulopustular eruptions were evaluated clinically and monitored by clinical photos. Skin biopsies, from ten patients taken before and after 1 month of treatment from each treatment area, were stained for EGFR and pEGFR.RESULTS: Application of vitamin K3 cream twice daily during treatment with cetuximab did not reduce the number of papulopustular eruptions, and this was independent of the use of systemic tetracycline. No significant changes in the staining of EGFR or pEGFR were observed in the skin of the vitamin K3-treated area compared to the placebo area.CONCLUSION: The present data do not support any clinical or immunohistochemical benefit of using vitamin K3 cream for cetuximab-induced rash.

AB - PURPOSE: Cetuximab inhibits the epidermal growth factor receptor (EGFR), and papulopustular eruptions is a frequent side effect. Vitamin K3 (menadione) has preclinically shown to be a potential activator of the EGFR by phosphorylating the receptor (pEGFR). The present randomised study investigated the effect of a vitamin K3 cream on cetuximab-induced rash.MATERIALS AND METHODS: Thirty patients were included in this double-blinded placebo-controlled trial. Patients receiving cetuximab 500 mg/m(2) every second week plus chemotherapy for metastatic cancer were included. In each patient, vitamin K3 cream and placebo were applied twice daily on two separate areas of the skin of minimum 10 × 10 cm for up to 2 months. Papulopustular eruptions were evaluated clinically and monitored by clinical photos. Skin biopsies, from ten patients taken before and after 1 month of treatment from each treatment area, were stained for EGFR and pEGFR.RESULTS: Application of vitamin K3 cream twice daily during treatment with cetuximab did not reduce the number of papulopustular eruptions, and this was independent of the use of systemic tetracycline. No significant changes in the staining of EGFR or pEGFR were observed in the skin of the vitamin K3-treated area compared to the placebo area.CONCLUSION: The present data do not support any clinical or immunohistochemical benefit of using vitamin K3 cream for cetuximab-induced rash.

KW - Journal Article

U2 - 10.1007/s00520-017-3623-x

DO - 10.1007/s00520-017-3623-x

M3 - Journal article

C2 - 28197850

VL - 25

SP - 2179

EP - 2185

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 7

ER -